The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
Open accessAbstract
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo‐like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence‐based or rely on expert opinion. The degree of consent among all task force members was included. Results: Treatment depends on the severity of BP and patients' comorbidities. High‐potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B‐cell‐depleting therapy and intravenous immunoglobulins may be considered in treatment‐resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions: The guidelines for the management of BP were updated. They summarize evidence‐ and expert‐based recommendations useful in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schmidt, E., & Zillikens, D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61140-4 · Cited by 1,015
Self-citationGrossman, J. M., Gordon, R., Ranganath, V. K., Deal, C., Caplan, L., Chen, W., Curtis, J. R., Furst, D. E., McMahon, M., Patkar, N. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20295 · Cited by 708
A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid
Joly, P., Roujeau, J.-C., Benichou, J., Picard, C., Dreno, B., Delaporte, E., Vaillant, L., D'Incan, M., Plantin, P., Bedane, C., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011592 · Cited by 626
Self-citationMolecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting.
Labib, R. S., Anhalt, G. J., Patel, H. P., Mutasim, D. F., & Diaz, L. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.4.1231 · Cited by 515
Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment
Bernard, P., & Antonicelli, F. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0264-2 · Cited by 257
Nicotinamide and Tetracycline Therapy of Bullous Pemphigoid
Fivenson, D. P. (1994) · Archives of Dermatology · doi:10.1001/archderm.130.6.753 · Cited by 250
The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations
Kridin, K., & Ludwig, R. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00220 · Cited by 248
Self-citationJoly, P., Roujeau, J.-C., Benichou, J., Delaporte, E., D'Incan, M., Dreno, B., Bedane, C., Sparsa, A., Gorin, I., Picard, C., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.412 · Cited by 241
Self-citationBritish Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012
Venning, V. A., Taghipour, K., Mohd Mustapa, M. F., Highet, A. S., Kirtschig, G., Hughes, J. R., McLelland, J., McDonagh, A. J., Punjabi, S., Buckley, D. A., et al. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12072 · Cited by 227
Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., Chalmers, J. R., Childs, M., Walton, S., Harman, K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30560-3 · Cited by 226
Self-citationAmber, K. T., Murrell, D. F., Schmidt, E., Joly, P., & Borradori, L. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8633-4 · Cited by 219
Self-citationDupilumab as a novel therapy for bullous pemphigoid: A multicenter case series
Abdat, R., Waldman, R. A., de Bedout, V., Czernik, A., Mcleod, M., King, B., Gordon, S., Ahmed, R., Nichols, A., Rothe, M., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.01.089 · Cited by 210
Gammon, W. R., Kowalewski, C., Chorzelski, T. P., Kumar, V., Briggaman, R. A., & Beutner, E. H. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70094-x · Cited by 204
Self-citationMulticenter prospective study of the humoral autoimmune response in bullous pemphigoid
Di Zenzo, G., Thoma-Uszynski, S., Fontao, L., Calabresi, V., Hofmann, S. C., Hellmark, T., Sebbag, N., Pedicelli, C., Sera, F., Lacour, J.-P., et al. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.04.012 · Cited by 192
Self-citationRituximab in autoimmune bullous diseases: mixed responses and adverse effects
Schmidt, E., Seitz, C. S., Benoit, S., Bröcker, E. B., & Goebeler, M. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07646.x · Cited by 189
Self-citationPathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab
Fairley, J. A., Baum, C. L., Brandt, D. S., & Messingham, K. N. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.035 · Cited by 154
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
Tasanen, K., Varpuluoma, O., & Nishie, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01238 · Cited by 126
Self-citationA randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid
Amagai, M., Ikeda, S., Hashimoto, T., Mizuashi, M., Fujisawa, A., Ihn, H., Matsuzaki, Y., Ohtsuka, M., Fujiwara, H., Furuta, J., et al. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.11.003 · Cited by 95
Fichel, F., Barbe, C., Joly, P., Bédane, C., Vabres, P., Truchetet, F., Aubin, F., Michel, C., Jegou, J., Grange, F., et al. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.5757 · Cited by 86
Self-citationSticherling, M., Franke, A., Aberer, E., Gläser, R., Hertl, M., Pfeiffer, C., Rzany, B., Schneider, S. W., Shimanovich, I., Werfel, T., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15649 · Cited by 81
Self-citationEgeberg, A., Schwarz, P., Harsløf, T., Andersen, Y. M. F., Pottegård, A., Hallas, J., & Thyssen, J. P. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.4968 · Cited by 78
Immunoadsorption in Dermatology
Meyersburg, D., Schmidt, E., Kasperkiewicz, M., & Zillikens, D. (2012) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2012.01075.x · Cited by 71
Self-citationPrognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis
Liu, Y., Wang, Y., Ye, Y.-C., Zhao, W., & Li, L. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1736-1 · Cited by 43
Sadik, C. D., Langan, E. A., Gutzmer, R., Fleischer, M. I., Loquai, C., Reinhardt, L., Meier, F. E., Göppner, D., Herbst, R. A., Zillikens, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588582 · Cited by 43
Self-citationInterventions for bullous pemphigoid
Singh, S., Kirtschig, G., Anchan, V. N., Chi, C., Taghipour, K., Boyle, R. J., & Murrell, D. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002292.pub4 · Cited by 38
Self-citation
Cited by
Understanding CD4+ T cells in autoimmune bullous diseases
Lee, A. Y., Kim, T., & Kim, J. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161927 · Cited by 13
Metadata
- Authors
- Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R., Böckle, B. C., Caproni, M., Caux, F., Chandran, N. S., Cianchini, G., Daneshpazhooh, M., De, D., Didona, D., Di Zenzo, G. M., Dmochowski, M., Drenovska, K., Ehrchen, J., Goebeler, M., Groves, R., Günther, C., Horvath, B., Hertl, M., Hofmann, S., Ioannides, D., Itzlinger‐Monshi, B., Jedličková, J., Kowalewski, C., Kridin, K., Lim, Y. L., Marinovic, B., Marzano, A. V., Mascaro, J. ‐., Meijer, J. M., Murrell, D., Patsatsi, K., Pincelli, C., Prost, C., Rappersberger, K., Sárdy, M., Setterfield, J., Shahid, M., Sprecher, E., Tasanen, K., Uzun, S., Vassileva, S., Vestergaard, K., Vorobyev, A., Vujic, I., Wang, G., Wozniak, K., Yayli, S., Zambruno, G., Zillikens, D., Schmidt, E., & Joly, P.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2022-06-29
- Volume
- 36
- Issue
- 10
- Pages
- 1689-1704
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W4283722628
- Cited by
- 277
- References
- 25
- FWCI
- 29.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.